Nurit Hollander Selected Research

Neoplasms (Cancer)

1/2017	Altered N-Linked Glycosylation in Follicular Lymphoma and Chronic Lymphocytic Leukemia: Involvement in Pathogenesis and Potential Therapeutic Targeting.
5/2011	Stress conditioning in mice: alterations in immunity and tumor growth.
5/2009	Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
3/2009	Bispecific antibodies for cancer therapy.
1/2009	Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma.
3/2008	Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin.
7/2007	Environmental enrichment augments the efficacy of idiotype vaccination for B-cell lymphoma.
9/2005	B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.
10/2004	Anti-idiotype x anti-CD44 bispecific antibodies inhibit invasion of lymphoid organs by B cell lymphoma.
3/2003	Anti-idiotype x anti-LFA-1 bispecific antibodies inhibit metastasis of B cell lymphoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nurit Hollander Research Topics

Disease

11	Neoplasms (Cancer) 01/2017 - 03/2002
7	B-Cell Lymphoma (Lymphoma, B Cell) 01/2017 - 03/2003
4	Lymphoma (Lymphomas) 01/2017 - 01/2009
4	Plasmacytoma 02/2009 - 03/2002
2	Neoplasm Metastasis (Metastasis) 10/2004 - 03/2003
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2017
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2017
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2012
1	Shock 05/2011
1	Residual Neoplasm 03/2008
1	Multiple Myeloma 09/2005

Drug/Important Bio-Agent (IBA)

6	AntigensIBA 01/2017 - 03/2002
5	AntibodiesIBA 01/2012 - 03/2002
5	VaccinesIBA 05/2009 - 09/2005
4	Bispecific AntibodiesIBA 01/2012 - 03/2003
4	Immunoglobulin Idiotypes (Idiotype, Immunoglobulin)IBA 01/2009 - 03/2002
3	Immunoglobulins (Immunoglobulin)IBA 01/2017 - 03/2008
2	Rituximab (Mabthera)FDA Link 01/2012 - 05/2009
2	Anti-Idiotypic AntibodiesIBA 03/2008 - 07/2007
2	Immunoglobulin M (IgM)IBA 03/2008 - 03/2002
2	adhesion receptorIBA 10/2004 - 03/2003
1	LectinsIBA 01/2017
1	Immunoglobulin Variable RegionIBA 01/2017
1	Mannose (D-Mannose)IBA 01/2017
1	OligosaccharidesIBA 01/2017
1	Polysaccharides (Glycans)IBA 01/2017
1	B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA 01/2017
1	Monoclonal AntibodiesIBA 01/2012
1	Immune Checkpoint InhibitorsIBA 01/2012
1	MitogensIBA 05/2011
1	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 05/2009
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2009
1	Radioisotopes (Radionuclides)IBA 03/2009
1	Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA 03/2003

Therapy/Procedure

6	Therapeutics 01/2017 - 10/2004
5	Immunotherapy 01/2012 - 03/2002
2	Drug Therapy (Chemotherapy) 05/2009 - 02/2009